Proffered paper session - Gastrointestinal tumours, colorectal
Proffered paper session - Gastrointestinal tumours, colorectal - Invited Discussant LBA20, 452O and LBA21
Date
22 Oct 2018Session
Proffered paper session - Gastrointestinal tumours, colorectalPresenters
Claus-Henning KoehneAuthors
C. KoehneAuthor affiliations
- Klinikum Oldenburg, 26133 - Oldenburg/DE
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
Proffered paper session - Gastrointestinal tumours, colorectal - Invited Discussant LBA18_PR and LBA19
Presenter: Julien Taieb
Session: Proffered paper session - Gastrointestinal tumours, colorectal
Resources:
Slides
Webcast
1777 - DPYD genotype-guided dose individualization of fluoropyrimidine therapy: A prospective safety and cost-analysis on DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A
Presenter: Linda Henricks
Session: Proffered paper session - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
3298 - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal Cancer (mCRC)
Presenter: Heinz-Josef Lenz
Session: Proffered paper session - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
6611 - Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy
Presenter: Axel Grothey
Session: Proffered paper session - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
5040 - TRIBE2: a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts).
Presenter: Chiara Cremolini
Session: Proffered paper session - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
5222 - InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial.
Presenter: Sheela Rao
Session: Proffered paper session - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast